Limits...
New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.

Kanda T, Nakamoto S, Wu S, Yokosuka O - Ther Clin Risk Manag (2014)

Bottom Line: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepato cellular carcinoma.In the USA, Canada, and Japan, simeprevir - one of the second-generation HCV NS3/4A protease inhibitors - in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice.In the near future, the development of interferon-free regimens with simeprevir is expected.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT
Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepato cellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second-generation HCV NS3/4A protease inhibitors - in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice. This review summarizes the mechanism of action of simeprevir and the results of clinical trials of simeprevir and peginterferon plus ribavirin for HCV genotype 1 patients. In general, the simeprevir and peginterferon plus ribavirin treatment is highly effective and its adverse events are similar to those of peginterferon plus ribavirin only, the exception being milder, reversible jaundice. In the near future, the development of interferon-free regimens with simeprevir is expected. Careful attention should be paid to new results of clinical trials with simeprevir.

No MeSH data available.


Related in: MedlinePlus

SVR12 in four Phase III Japanese hepatitis C virus genotype 1 patients treated with (A and B) simeprevir and ribavirin plus peginterferon α-2a or (C) peginterferon α-2b. (A) CONCERTO-1 trials for treatment-naïve patients; (B) CONCERTO-2 and CONCERTO-3 trials for prior non-responders and prior relapsers, respectively; and (C) CONCERTO-4 trials for treatment-naïve patients, prior non-responders, and prior relapsers. Data from Hayashi et al,25 Izumi et al,26 and Suzuki et al.27Abbreviations: CONCERTO-1, A Study of the Efficacy of Combination Therapy Including Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-2/3, A Study of the Efficacy of Retreatment with Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-4, A Study of the Efficacy of Combination Therapy with Simeprevir (TMC435), Peginterferon α-2b, and Ribavirin in the Treatment of Genotype 1 Hepatitis C; SVR12, sustained virologic response 12 weeks after the end of treatment; wks, weeks.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4043814&req=5

f4-tcrm-10-387: SVR12 in four Phase III Japanese hepatitis C virus genotype 1 patients treated with (A and B) simeprevir and ribavirin plus peginterferon α-2a or (C) peginterferon α-2b. (A) CONCERTO-1 trials for treatment-naïve patients; (B) CONCERTO-2 and CONCERTO-3 trials for prior non-responders and prior relapsers, respectively; and (C) CONCERTO-4 trials for treatment-naïve patients, prior non-responders, and prior relapsers. Data from Hayashi et al,25 Izumi et al,26 and Suzuki et al.27Abbreviations: CONCERTO-1, A Study of the Efficacy of Combination Therapy Including Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-2/3, A Study of the Efficacy of Retreatment with Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-4, A Study of the Efficacy of Combination Therapy with Simeprevir (TMC435), Peginterferon α-2b, and Ribavirin in the Treatment of Genotype 1 Hepatitis C; SVR12, sustained virologic response 12 weeks after the end of treatment; wks, weeks.

Mentions: Four Phase III Japanese studies of simeprevir QD demonstrated SVR 12 weeks after the end of treatment (SVR12) in HCV genotype 1 patients (Figure 4).25–27


New treatments for genotype 1 chronic hepatitis C - focus on simeprevir.

Kanda T, Nakamoto S, Wu S, Yokosuka O - Ther Clin Risk Manag (2014)

SVR12 in four Phase III Japanese hepatitis C virus genotype 1 patients treated with (A and B) simeprevir and ribavirin plus peginterferon α-2a or (C) peginterferon α-2b. (A) CONCERTO-1 trials for treatment-naïve patients; (B) CONCERTO-2 and CONCERTO-3 trials for prior non-responders and prior relapsers, respectively; and (C) CONCERTO-4 trials for treatment-naïve patients, prior non-responders, and prior relapsers. Data from Hayashi et al,25 Izumi et al,26 and Suzuki et al.27Abbreviations: CONCERTO-1, A Study of the Efficacy of Combination Therapy Including Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-2/3, A Study of the Efficacy of Retreatment with Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-4, A Study of the Efficacy of Combination Therapy with Simeprevir (TMC435), Peginterferon α-2b, and Ribavirin in the Treatment of Genotype 1 Hepatitis C; SVR12, sustained virologic response 12 weeks after the end of treatment; wks, weeks.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4043814&req=5

f4-tcrm-10-387: SVR12 in four Phase III Japanese hepatitis C virus genotype 1 patients treated with (A and B) simeprevir and ribavirin plus peginterferon α-2a or (C) peginterferon α-2b. (A) CONCERTO-1 trials for treatment-naïve patients; (B) CONCERTO-2 and CONCERTO-3 trials for prior non-responders and prior relapsers, respectively; and (C) CONCERTO-4 trials for treatment-naïve patients, prior non-responders, and prior relapsers. Data from Hayashi et al,25 Izumi et al,26 and Suzuki et al.27Abbreviations: CONCERTO-1, A Study of the Efficacy of Combination Therapy Including Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-2/3, A Study of the Efficacy of Retreatment with Simeprevir (TMC435) in the Treatment of Genotype 1 Hepatitis C; CONCERTO-4, A Study of the Efficacy of Combination Therapy with Simeprevir (TMC435), Peginterferon α-2b, and Ribavirin in the Treatment of Genotype 1 Hepatitis C; SVR12, sustained virologic response 12 weeks after the end of treatment; wks, weeks.
Mentions: Four Phase III Japanese studies of simeprevir QD demonstrated SVR 12 weeks after the end of treatment (SVR12) in HCV genotype 1 patients (Figure 4).25–27

Bottom Line: Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepato cellular carcinoma.In the USA, Canada, and Japan, simeprevir - one of the second-generation HCV NS3/4A protease inhibitors - in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice.In the near future, the development of interferon-free regimens with simeprevir is expected.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ABSTRACT
Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepato cellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second-generation HCV NS3/4A protease inhibitors - in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved for HCV genotype 1-infected patients and is now used in daily clinical practice. This review summarizes the mechanism of action of simeprevir and the results of clinical trials of simeprevir and peginterferon plus ribavirin for HCV genotype 1 patients. In general, the simeprevir and peginterferon plus ribavirin treatment is highly effective and its adverse events are similar to those of peginterferon plus ribavirin only, the exception being milder, reversible jaundice. In the near future, the development of interferon-free regimens with simeprevir is expected. Careful attention should be paid to new results of clinical trials with simeprevir.

No MeSH data available.


Related in: MedlinePlus